RabMAb

Anti-Tau (phospho S396) antibody [EPR2731] (ab109390)

Overview

  • Product nameAnti-Tau (phospho S396) antibody [EPR2731]
    See all Tau primary antibodies
  • Description
    Rabbit monoclonal [EPR2731] to Tau (phospho S396)
  • SpecificityThis antibody only detects Tau phosphorylated at serine 396.
  • Tested applicationsICC/IF, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Tau.

  • Positive control
    • SH-SY5Y cell lysates, untreated.
  • General notes

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated ‘PUR’ on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A 40 µl trial size is available to purchase for this antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab109390 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/50.
IHC-P 1/4000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
WB 1/10000 - 1/50000. Predicted molecular weight: 79 kDa.

For unpurified, use 1/10000 - 1/50000.

  • Application notesIs unsuitable for IP.
  • Target

    • FunctionPromotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
    • Tissue specificityExpressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
    • Involvement in diseaseNote=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
      Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
      Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
      Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
      Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
    • Sequence similaritiesContains 4 Tau/MAP repeats.
    • Developmental stageFour-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
    • DomainThe tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
    • Post-translational
      modifications
      Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
      Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
      Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
    • Cellular localizationCytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
    • Information by UniProt
    • Database links
    • FormThere are 9 isoforms produced by alternative splicing.
    • Alternative names
      • AI413597 antibody
      • AW045860 antibody
      • DDPAC antibody
      • FLJ31424 antibody
      • FTDP 17 antibody
      • G protein beta1/gamma2 subunit interacting factor 1 antibody
      • MAPT antibody
      • MAPTL antibody
      • MGC134287 antibody
      • MGC138549 antibody
      • MGC156663 antibody
      • Microtubule associated protein tau antibody
      • Microtubule associated protein tau isoform 4 antibody
      • Microtubule-associated protein tau antibody
      • MSTD antibody
      • Mtapt antibody
      • MTBT1 antibody
      • MTBT2 antibody
      • Neurofibrillary tangle protein antibody
      • Paired helical filament tau antibody
      • Paired helical filament-tau antibody
      • PHF tau antibody
      • PHF-tau antibody
      • PPND antibody
      • pTau antibody
      • RNPTAU antibody
      • TAU antibody
      • TAU_HUMAN antibody
      • Tauopathy and respiratory failure, included antibody
      see all

    Anti-Tau (phospho S396) antibody [EPR2731] images

    • All lanes : Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/20000 dilution (purified)

      Lane 1 : Untreated SH-SY5Y
      Lane 2 : SH-SY5Y treated with alkaline phosphatase

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP goat ant-rabbit (H+L) at 1/1000 dilution

      Predicted band size : 79 kDa
      Additional bands at : 50-70 kDa. We are unsure as to the identity of these extra bands.

      Blocking buffer: 5% NFDM/TBST

      Dilution buffer: 5% NFDM/TBST

    • Immunohistochemical staining of paraffin embedded human glioblastoma with purified ab109390 at a dilution of 1/4000. A pre-diluted HRP polymer for rabbit/mouse IgG was used as the secondary antibody and the sample was counter-stained wirh hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.

    • Immunofluorescent staining of Neuro-2a cells (fixed in 4% PFA, permeabilized with 0.1% Triton X 100) using purified ab109390 at a dilution of 1/50. An Alexa Fluor® 488 goat anti-rabbit antibody was used as the secondary at a dilution of 1/500 and the cells were counter stained with DAPI. The negative control is shown in the bottom right hand panel - for the negative control, Alex Fluor® 594 goat anti-mouse was used at a dilution of 1/500.

    • Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/5000 dilution (purified) + Mouse brain at 10 µg

      Secondary
      HRP goat anti-rabbit (H+L) at 1/1000 dilution

      Predicted band size : 79 kDa
      Additional bands at : 50-70 kDa. We are unsure as to the identity of these extra bands.

      Blocking buffer: 5% NFDM/TBST

      Dilution buffer: 5% NFDM/TBST

    • IHC image of Tau (phospho S396) staining in human Alzheimer hippocampus formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with citrate buffer. The section was then incubated with unpurified ab109390 at 1/1000 dilution for 2 hoursat 21ºC. A biotin conjugated goat-anti-rabbit antibody was used as a secondary at 1/250. The section shows clear neurofibrillary tangles in a subset of neurons.

      See Abreview

    • All lanes : Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/10000 dilution (unpurified)

      Lane 1 : SH-SY5Y cell lysates, untreated
      Lane 2 : SH-SY5Y cell lysates, treated with Alkaline Phosphatase

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 79 kDa

    References for Anti-Tau (phospho S396) antibody [EPR2731] (ab109390)

    This product has been referenced in:
    • Murakami K  et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid ß protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 286:44557-68 (2011). WB . Read more (PubMed: 22072713) »

    See 1 Publication for this product

    Product Wall

    Application Western blot
    Loading amount 10 µg
    Gel Running Conditions Reduced Denaturing (10%)
    Sample Human Cell lysate - whole cell (human stem cell derived neurons (healthy/diseased))
    Specification human stem cell derived neurons (healthy/diseased)
    Treatment quinolinic acid 72h (and non treated)
    Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: rt°C
    Username

    Abcam user community

    Verified customer

    Submitted Mar 26 2014

    Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Blocking step (agent) for 10 minute(s) · Concentration: 1% · Temperature: 21°C
    Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citric acid
    Sample Human Tissue sections (Brain)
    Specification Brain
    Permeabilization No
    Fixative Formaldehyde
    Username

    Mr. Carl Hobbs

    Verified customer

    Submitted Dec 12 2013

    Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Blocking step BSA as blocking agent for 10 minute(s) · Concentration: 1% · Temperature: 21°C
    Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citric acid
    Sample Human Tissue sections (Tau/APP transgenic mouse brain expressing human Ta)
    Specification Tau/APP transgenic mouse brain expressing human Ta
    Permeabilization No
    Fixative Formaldehyde
    Username

    Mr. Carl Hobbs

    Verified customer

    Submitted Dec 12 2013

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"